Clarent Biopharma, Inc.

This study is testing a new oral medication called RAP-103 to see if it can reduce the severity of psoriasis and improve patients' quality of life. It will involve about 90 adults with moderate-to-severe plaque psoriasis, who will take either the drug at one of two doses or a pla…